US court affirms Seroquel sum

RNS Number : 7267Z

AstraZeneca PLC

28 September 2009

 



US COURT OF APPEALS AFFIRMS SUMMARY JUDGMENT DECISION IN SEROQUEL PATENT LITIGATION

AstraZeneca today announced that the US Court of Appeals for the Federal Circuit has affirmed the Summary Judgment decision of No Inequitable Conduct in patent litigation involving SEROQUEL (quetiapine fumarate) tablets. In July 2008, AstraZeneca announced that the US District Court for the District of New Jersey granted the company's Motion for Summary Judgment of No Inequitable Conduct in litigation involving Teva Pharmaceutical Industries Ltd. and Sandoz, Inc.  

This most recent decision, made public on 25 September 2009, upholds the District Court's judgment that Teva's and Sandoz's products will infringe AstraZeneca's SEROQUEL patent and that the patent is valid and enforceable. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs). Teva and Sandoz had conceded infringement and the validity of AstraZeneca's patent covering SEROQUEL. The ANDAs sought approval to market generic versions of SEROQUEL tablets in the US before SEROQUEL's patent expires. The patent covering SEROQUEL expires in September 2011, with paediatric exclusivity through March 2012.  

Since the Federal Circuit Court of Appeals' affirmed Summary Judgment in favor of AstraZeneca, trial remains unnecessary.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.  For more information about AstraZeneca, please visit: www.astrazeneca.com.

Media Enquiries:
Chris Sampson	[phone] (24 hours)
Neil McCrae	[phone] (24 hours)
Sarah Lindgreen	[phone] (24 hours)
Kirsten Evraire (US)	+ 1 302 885 0435
Investor Enquiries UK:
Jonathan Hunt	[phone]	mob: [phone]
Karl Hard	[phone]	mob: [phone]
Investor Enquiries US:
Ed Seage	[phone]	mob: [phone]
Jorgen Winroth	[phone]	mob: [phone]

28 September 2009

- ENDS -

 

END

 

 

MSCGGGZLNNMGLZM